BARCELONA (MedPage Today) -- Four studies testing the injectable novel lipid-lowering agent alirocumab found the drug dramatically reduced LDL-cholesterol (LDL-C) among high-risk patients who had not achieved LDL targets using maximum tolerated statin therapy and/or ezetimibe. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment